High-dose cyclophosphamide for autoimmunity and alloimmunity

Robert A. Brodsky

doi:10.1007/s12026-009-8149-y

High-dose cyclophosphamide for autoimmunity and alloimmunity

Robert A. Brodsky

School of Medicine

Research output: Contribution to journal › Review article › peer-review

27 Scopus citations

Abstract

High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.

Original language	English (US)
Pages (from-to)	179-184
Number of pages	6
Journal	Immunologic Research
Volume	47
Issue number	1-3
DOIs	https://doi.org/10.1007/s12026-009-8149-y
State	Published - Jul 2010

Keywords

Aplastic anemia
Autoimmunity
Bone marrow transplantation
Cyclophosphamide

ASJC Scopus subject areas

Immunology

Access to Document

10.1007/s12026-009-8149-y

Cite this

@article{7ae1b43a28ee4abeb4748992f7a1dc86,

title = "High-dose cyclophosphamide for autoimmunity and alloimmunity",

abstract = "High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.",

keywords = "Aplastic anemia, Autoimmunity, Bone marrow transplantation, Cyclophosphamide",

author = "Brodsky, {Robert A.}",

note = "Funding Information: Acknowledgments Supported in part by National Institutes of Health Grants CA70970. Under a licensing agreement between Accentia Pharmaceuticals and the Johns Hopkins University, Dr. Brodsky is entitled to a share of royalty received by the University on sales of a method of administering high-dose cyclophosphamide. The study described in this article could impact the value of this method of administering the drug. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.",

year = "2010",

month = jul,

doi = "10.1007/s12026-009-8149-y",

language = "English (US)",

volume = "47",

pages = "179--184",

journal = "Immunologic Research",

issn = "0257-277X",

publisher = "Humana Press",

number = "1-3",

}

TY - JOUR

T1 - High-dose cyclophosphamide for autoimmunity and alloimmunity

AU - Brodsky, Robert A.

N1 - Funding Information: Acknowledgments Supported in part by National Institutes of Health Grants CA70970. Under a licensing agreement between Accentia Pharmaceuticals and the Johns Hopkins University, Dr. Brodsky is entitled to a share of royalty received by the University on sales of a method of administering high-dose cyclophosphamide. The study described in this article could impact the value of this method of administering the drug. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

PY - 2010/7

Y1 - 2010/7

N2 - High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.

AB - High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.

KW - Aplastic anemia

KW - Autoimmunity

KW - Bone marrow transplantation

KW - Cyclophosphamide

UR - http://www.scopus.com/inward/record.url?scp=77953958346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953958346&partnerID=8YFLogxK

U2 - 10.1007/s12026-009-8149-y

DO - 10.1007/s12026-009-8149-y

M3 - Review article

C2 - 20087683

AN - SCOPUS:77953958346

SN - 0257-277X

VL - 47

SP - 179

EP - 184

JO - Immunologic Research

JF - Immunologic Research

IS - 1-3

ER -

High-dose cyclophosphamide for autoimmunity and alloimmunity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this